PowerShares Dynamic Pharmaceuticals ETF

In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017.

Merck & Co.’s (MRK) Januvia generated revenues of $927 million in the third quarter, reflecting an ~8% YoY (year-over-year) decline.

Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

The Healthcare Select Sector SPDR ETF’s (XLV) price has increased ~14.6% in the third quarter, and its year-to-date returns increased ~15.5% on October 2.

Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue.

Merck & Co. (MRK) stock has risen ~3.2% in the same period, with a closing price of $70.78 on September 24.

SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.

In this article, we’ll discuss the details of the dividends paid by the pharmaceutical stocks under review in this series.

Allergan’s US Specialized Therapeutics segment reported revenue of $1.83 billion in the second quarter.

Pfizer (PFE) reported a rise in revenue in international markets during the second quarter. Lower sales from its US markets offset this rise.

Amgen (AMGN) stock has risen 6.2% over the last 12 months, and ~9.5% year-to-date.

Leading pharmaceutical company Allergan (AGN), which deals in generic and specialty pharmaceutical products, segregated its business into three segments: US General Medicines, US Specialized Therapeutics, and International.

Eli Lilly’s net adjusted income increased to ~$1.4 billion during Q1 2018, compared to net adjusted income of $1.0 billion during Q1 2017.

As discussed earlier, Pfizer’s (PFE) international revenue grew in Q1 2018, while its US sales fell.

Eli Lilly’s stock price has fallen nearly 11.2% in the last 12 months and nearly 11.5% in 2018 year-to-date.

Eliquis is one of Bristol-Myers Squibb’s (BMY) top-selling cardiovascular drugs.

Pfizer reported revenue of ~$6.5 billion in US markets during 4Q17, a 4% fall compared to ~$6.8 billion in 4Q16.

In his first State of the Union speech, President Trump didn’t have any surprises for the markets. Financial markets were anxious before the speech.

On January 22, Vermont decriminalized the possession of marijuana for adults 21 and older. Vermont became the ninth state to legalize marijuana for recreational purposes.

Products under the Kirin–Amgen joint venture include Epogen, Neulasta, Aranesp, Nplate, and Neupogen.

In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.

In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

Johnson & Johnson’s (JNJ) gross profit margin decreased to 64.9% during 3Q17, a decline of ~4.0% compared to the gross profit margin of 69.2% during 3Q16.

US markets contributed 55% of Eli Lilly’s total revenues in 3Q17. US sales rose 9% to $3.1 billion in 3Q17 compared to 3Q16.

Invokanna reported year-to-date (or YTD) September 2017 revenues of $844 million compared to $1.0 billion in YTD (year-to-date) September 2016.

The oncology portfolio Bristol-Myers Squibb’s (BMY) oncology portfolio includes key products Empliciti, Opdivo, Sprycel, and Yervoy. The oncology portfolio contributes over 40% of Bristol-Myers Squibb’s total revenue. Empliciti The above chart compares key oncology products’ revenue over the last few quarters. Empliciti is the latest drug launched by Bristol-Myers Squibb for the treatment of multiple myeloma. […]

In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals’ (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.

For 3Q17, Keytruda reported revenues of ~$1.1 billion, a 194% growth compared to revenues of $356 million in 3Q16.

In 3Q17, Pfizer’s (PFE) Premarin generated revenues of $238 million, a ~2% decline on a YoY basis and a 3% decline on a quarter-over-quarter basis.

In 3Q17, Eli Lilly’s overall revenues from oncology products fell due to lower sales of Alimta, Erbitux, and Portrazza, offset by a rise in Cyramza sales.

Bridion revenue In 3Q17, Merck’s (MRK) Bridion reported revenue of $185 million, which reflected ~33% growth YoY (year-over-year) and 13% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Bridion generated revenue of $495 million, which reflected 44% growth YoY. Growth in US sales volumes primarily contributed to the drug’s revenue growth in the two […]

Immunology drug revenue In 3Q17, Remicade generated revenue of $214 million, a ~31% fall YoY (year-over-year) and 3% growth QoQ (quarter-over-quarter). During the first nine months of 2017, Remicade reported revenue of $651 million, which reflected a ~35% fall YoY. Foreign exchange had a 3% favorable effect towards 3Q17 Remicade revenue. In 3Q17, Simponi reported revenue of […]

The latest report was released on November 3 and indicated that the goods and services deficit was $43.5 billion in September, or $0.7 billion higher than in August.

In October 2017, the FDA approved Pfizer’s Lyrica CR (pregabalin), a once-daily extended-release tablet for the management of postherpatic neuralgia.

In 1H17, Valeant Pharmaceuticals International’s (VRX) U.S. Diversified Products franchise reported revenues of $519.0 million compared to $848.0 million in 1H17.

Calendar 3Q17 saw several major mergers and acquisitions in the US pharmaceutical industry.

Bristol-Myers Squibb’s (BMY) cardiovascular portfolio includes the blockbuster drug Eliquis, developed in alliance with Pfizer (PFE).

Johnson & Johnson (JNJ) reported revenues of $18.8 billion in 2Q17, a 2% increase as compared to revenues of $18.5 billion in 2Q16.

Merck’s (MRK) diabetes portfolio includes drugs used for controlling the blood sugar levels for patients with diabetes.

In August 2017, JAZZ’s Vyxeos liposome injection for the treatment of adult individuals with rapidly progressing or life t-AML received FDA approval.

On July 31, 2017, Eli Lilly and Boehringer Ingelheim announced that the companies would support one of the new programs by the American College of Cardiology.

Forteo is used for the treatment of osteoporosis. Forteo’s sales totaled $446.7 million during 2Q17, a 22.0% increase compared to $367.6 million in 2Q16.

Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.

In August 2017, the Arthritis Advisory Committee of the FDA recommended a positive opinion for the proposed dose of Xeljanz for the treatment of individuals with active psoriatic arthritis.

In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.

Orencia revenues rose to $650.0 million in 2Q17, a 10.0% rise compared to $593 million in 2Q16.

In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.

The US Specialized Therapeutics segment reported revenues of $1.7 billion in 2Q17, a 15.2% increase as compared to $1.5 billion during 2Q16.

In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem reported revenues of ~$298 million, which represented a YoY (year-over-year) growth of ~6% and sequential growth of ~9%.

In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

In 2Q17, Celgene’s (CELG) Abraxane generated revenues of around $254 million, which reflected ~2% growth on a year-over-year basis.

The key products in Bristol-Myers Squibb’s (BMY) oncology portfolio include Empliciti, Opdivo, Sprycel, and Yervoy. Let’s take a closer look at these drugs and their performances.

In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

Eli Lilly’’s (LLY) Human Pharmaceuticals segment reported a rise of ~11.0% to ~$5.0 billion for 2Q17 compared to ~$4.6 billion for 2Q16.

In 2016, Pfizer’s (PFE) Lipitor reported revenues of ~$1.8 billion, which represented a ~5% YoY (year-over-year) fall.

Allergan’s (AGN) business has undergone several changes over the past few years due to acquisitions and divestitures.

A look at Bristol-Myers Squibb Headquartered in New York City, Bristol-Myers Squibb (BMY) is an American pharmaceutical company that develops innovative medicines in various therapeutic areas, including cardiovascular, neuroscience, immunoscience, oncology, and virology. Stock price performance While Bristol-Myers Squibb’s stock price has risen ~3.8% in 2Q17, it had fallen ~5.4% year-to-date as of July 7, […]

Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.

Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.

Heavyweight pharmaceutical company Johnson & Johnson (JNJ) reported earnings per share (or EPS) of $1.83 on revenue of $17.8 billion in 1Q17.

Combined sales for Januvia and Janumet were ~$1.3 billion for 1Q17, a ~5.0% fall from $1.4 billion in 1Q16.

On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.

The Virology segment is Bristol-Myers Squibb’s (BMY) second-largest revenue contributor. The segment contributes ~25% of the company’s total revenue.

JNJ’s overall business is classified into three segments: Pharmaceuticals, Consumer, and Medical Devices. At constant exchange rates, the company reported growth across all of its segments.

Johnson & Johnson’s (JNJ) Pharmaceuticals segment includes immunology, infectious disease, neuroscience, oncology, and cardiovascular and metabolics.

Abbott Laboratories’ stock price rose ~7.1% in 1Q17. On April 7, 2017, the stock’s price had risen 13.7% year-to-date (or YTD).

As discussed earlier, both Eli Lilly’s (LLY) Human Pharmaceuticals and Animal Health segments’ performances were positive in 2016.

Eli Lilly’s (LLY) business is classified into two segments: Human Pharmaceuticals and Animal Health.

Bausch & Lomb projections Valeant Pharmaceuticals expects its Bausch & Lomb/International segment to grow at a CAGR (compound average growth rate) of 4%–6% between 2017 and 2020. In 2017, the company expects the segment to grow 5%–7% after adjusting for foreign exchange fluctuations and the impact of impending patent expiries. In 2017, the segment is also expected […]

New product launches Despite upcoming patent expirations for drugs Elidel, Solodyn, and Acanya in 2018, and Zyclara in 2019, Valeant Pharmaceuticals (VRX) expects to boost its dermatology revenue after 2018 through new product launches. On December 12, 2016, the company hired Bill Humpries as executive vice president and head of the dermatology team. The change […]

Gastrointestinal franchise prescriptions In 2016, Valeant Pharmaceuticals’ (VRX) gastrointestinal (or GI) drugs Xifaxan, Uceris, Apris, and Relistor reported solid year-over-year (or YoY) growth in prescriptions, of around 18%, 6%, 4%, and 1%, respectively. Relistor growth trends Since the launch of the oral version of Relistor in 4Q16, the drug has witnessed a 13% rise in total […]

Harvoni, a combination drug of ledipasvir 90 mg and sofosbuvir 400 mg, is Gilead Sciences’ (GILD) biggest-selling drug.

Baxter has been actively involved in various research and development initiatives to provide better technology products and services to healthcare providers for better patient care.

Gilead Sciences (GILD) holds a share of nearly 80% in the antiretroviral therapy market, which covers ~840,000 patients.

Bristol-Myers Squibb (BMY) reported a growth of 21% to $4.9 billion in its 3Q16 results.

Overall, Eli Lilly’s (LLY) segment-wise performance in 3Q16 was positive for both its Human Pharmaceuticals and Animal Health segments.

Opdivo’s significant regulatory advances over the past quarter include approval for head and neck cancer indications, among others.

Merck & Co. has separated its business operations into two business segments: the Global Human Health business and the Animal Health business.

Baxter International (BAX) announced a quarterly cash dividend of $0.13 per share on July 19, 2016.

Although generic drugs are the same as branded drugs in terms of the medicinal effect, their prices are extremely low compared to the branded products.

While Clinton aims to retain and bolster the Affordable Care Act, Trump wants to replace it with a new act that encourages free-market competition.

Mylan’s 2Q16 revenues were mainly driven by 4% growth at constant exchange rates in its Generics segment, which reported a rise to $2.14 billion in 2Q16.

Mylan’s (MYL) revenues rose 8% at constant exchange rates in 2Q16, reporting revenues of ~$2.6 billion, as compared to its 2Q15 revenues of ~$2.4 billion.

There are six distinct genotypes of HCV (hepatitis C virus). If we know the genotype, recommending the treatment and duration becomes easier.

Danaher’s Environmental & Applied Solutions (or, EAS) segment represented 25% of company sales in 2015, or $3.5 billion in value terms.

Danaher’s filtration business came into existence through the acquisition of Pall in 2015.

Eli Lilly and Co.’s (LLY) overall business is classified into two business segments—Human Pharmaceuticals and Animal Health.

Akorn’s (AKRX) robust research and development pipeline is comprised of branded and generic drugs with a total addressable market value of about $9.2 billion.

Allergan’s (AGN) International segment includes the revenues from both branded products and aesthetics products outside the US markets.

Keytruda, a prescription medicine classified under Merck and Co.’s (MRK) Immuno-oncology franchise, is used to treat non-small cell lung cancer as well as melanoma.

Bristol-Myers Squibb (BMY) is expected to report revenue growth of over 11% to $4.7 billion in its 2Q16 results on July 28, 2016.

Analysts estimate an increase of ~3.4% in Eli Lilly and Company’s (LLY) 2Q16 revenues to reach ~$5.2 billion.

Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.

Allergan (AGN) estimates that its revenues will be around $17 billion in 2016.

Allergan’s (AGN) international brands segment includes revenues from both branded products and aesthetics products outside the US markets.

Allergan’s (AGN) Anda distribution segment distributes generic pharmaceutical products, vaccines, and over-the-counter products in the US markets.

The specialty segment reported an increase of 17% in revenues at $247.9 million in 1Q16 versus $211.1 million in 1Q15.